Efficacy and Safety of ES16001 in Patients With COVID-19
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is phase II/III, randomized, parallel-group, double-blind, placebo-controlled study.
Patients must be at least 19 years of age (or according to the legal age for adult in each
country) with confirmed mild or moderate COVID-19 tested positive with a real time reverse
transcription polymerase chain reaction (RT-PCR) analysis of rhinopharynx samples. RT-PCR
analysis of rhinopharynx samples must be <4 days old prior to the study enrolment